Viatris president Rajiv Malik to retire in April next year

New Delhi: Indian-born Rajiv Malik, president of the world’s largest generics drugmaker Viatris, will retire in April subsequent yr, the Nasdaq-listed firm has knowledgeable inventory exchanges.

Malik was instrumental within the $12 billion merger of Mylan with Pfizer’s generic drug unit that resulted within the creation of Viatris in 2019. The mixed entity’s gross sales are greater than that of Israel’s Teva, which was beforehand the most important generic drug firm on the planet.

“There will not be sufficient phrases to precise how a lot Rajiv Malik as each a companion and a pacesetter has meant to me, first at Mylan and now Vitara’s. He’s the rarest of people who possesses a very distinctive skillset. We couldn’t have reached all of our successes thus far with out him”, mentioned Robert J. Coury, government chairman, Viatris.

Malik will proceed to serve on the board of Viatris after his retirement, as per the inventory trade communication.

“I’m happy that Rajiv has agreed to stay on the board to make sure the continuity of his expertise and perception on the general operations of the corporate,” mentioned Coury.

Malik spent a big a part of his early profession at Ranbaxy, the place he was the top of world regulatory affairs and pharma analysis, earlier than transferring to Swiss drug maker Sandoz.